Top Markets
Coin of the day
Adagene Inc. Adagene Inc.

Adagene Inc.

ADAG
株式のランク #19938
Adagene Inc. functions as a clinical-stage biopharmaceutical organization,... Adagene Inc. functions as a clinical-stage biopharmaceutical organization, primarily concentrating on the identification, evolution, and fabrication of monoclonal antibody-based therapeutics engineered to combat various types of cancer. The company's developmental pipeline encompasses several investigational assets currently undergoing human trials. Among these is ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibody, which is navigating Phase 1b/2 clinical assessment for individuals with advanced solid tumors and non-Hodgkin's lymphoma. Additionally, Adagene is progressing ADG126, a fully-human anti-CTLA-4 mAb, and ADG116, another human ligand-blocking anti-CTLA-4 mAb, both of which are advancing through Phase 1 studies for the treatment of advanced or metastatic solid tumors. Further along, ADG104, an anti-PD-L1 mAb, is in Phase 2 clinical development, and the innovative anti-CSF-1R mAb, ADG125, is undergoing Phase 1 trials. Beyond its clinical-stage programs, the firm also maintains an active preclinical portfolio. This includes ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is being explored for hematologic and solid tumor indications; ADG138, a novel HER2xCD3 POWERbody designed to target HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody under investigation for its potential to minimize off-tumor toxicities. Adagene Inc. was founded in 2011 and its principal operations are based in Suzhou, China.
株価
$3.88
時価総額
$146.08M
変化(1日)
-0.51%
変化(1年)
65.11%
CN
取引 Adagene Inc. (ADAG)

カテゴリー

Adagene Inc.(ADAG)の株価履歴
終値の最高値: $3.95 (2026-08-01)

終値の最安値: $26.26 (2021-02-01)
Adagene Inc. の株価履歴(2021 ~ 2026)
年間株価パフォーマンス
パフォーマンス
2026 (TTM) 55.14%
2025 -10.40%
2024 22.17%
2023 38.55%
2022 -85.12%
2021 0.00%
類似企業または競合の株価
企業 株価 変化率 1年%
$553.09 42.20%
US
$1.02K 50.56%
NL
$158.64 525.80%
US
$122.47 -12.71%
AU
$772.27 8.67%
CH